Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the global market.
Summary
Eli Lilly has announced a significant partnership with Insilico, committing $2.75 billion to bring AI-developed pharmaceuticals to the global market.
The agreement includes an upfront payment of $115 million, which will facilitate the initial stages of drug development and commercialization.
This collaboration highlights the increasing integration of artificial intelligence in pharmaceutical research and development, potentially enhancing throughput and efficiency in drug discovery.
Updates
Update at 18:06 UTC on 2026-03-29
STAT reported Lilly has signed a deal with AI drug developer Insilico that’s worth $115 million up front and approximately $2.75 billion in biobucks.
Sources: STAT